Welcome to our dedicated page for Cytokinetics news (Ticker: CYTK), a resource for investors and traders seeking the latest updates and insights on Cytokinetics stock.
Cytokinetics, Incorporated (Nasdaq: CYTK) is a specialty cardiovascular biopharmaceutical company that regularly issues news about its medicines and programs in cardiac muscle dysfunction. Company updates frequently highlight MYQORZO (aficamten), a cardiac myosin inhibitor that Cytokinetics reports is approved in the United States and China for adults with symptomatic obstructive hypertrophic cardiomyopathy to improve functional capacity and symptoms, as well as related regulatory developments in other regions.
News for CYTK often covers key regulatory milestones such as positive opinions from the Committee for Medicinal Products for Human Use of the European Medicines Agency, approvals by national regulatory agencies and progress of New Drug Application reviews. Cytokinetics also reports on clinical trial data from studies like SEQUOIA-HCM and MAPLE-HCM, including results presented at major cardiology congresses and publications in peer-reviewed journals.
Investors and observers can find announcements about the company’s broader pipeline, including omecamtiv mecarbil in heart failure with severely reduced ejection fraction, ulacamten in heart failure with preserved ejection fraction and CK-089 in skeletal muscle disorders. Additional news items describe financial results, capital raising activities, inducement equity grants, executive appointments and participation in healthcare and investor conferences.
This CYTK news page aggregates these disclosures so readers can follow developments in Cytokinetics’ cardiovascular programs, regulatory interactions and corporate activities over time.
Cytokinetics (CYTK) announced the start of COMET-HF, a confirmatory Phase 3 clinical trial evaluating omecamtiv mecarbil in patients with symptomatic heart failure with severely reduced ejection fraction. The trial, conducted with Duke Clinical Research Institute, will enroll approximately 1,800 patients randomized 1:1 to receive omecamtiv mecarbil or placebo. The primary endpoint is time to first event in a composite of cardiovascular death, first heart failure event, LVAD implantation, cardiac transplantation, or stroke. Eligible patients must have ejection fraction <30%, NT-proBNP ≥1,000 pg/mL, and a heart failure event within six months. The study includes a two-week run-in period and two-week washout period before randomization.
Cytokinetics (CYTK) has announced its participation in two major investor conferences this December. The company will join the 7th Annual Evercore ISI HealthconX Conference for a fireside chat on December 3, 2024, at 9:35 AM ET in Coral Gables, FL. Additionally, they will participate in the 36th Annual Piper Sandler Healthcare Conference on December 4, 2024, at 8:00 AM ET in New York.
Both fireside chats will be accessible via live webcast through Cytokinetics' website's Investors & Media section, with recordings available for 90 days after the events.
Cytokinetics (CYTK) announced FDA acceptance of its New Drug Application (NDA) for aficamten, a cardiac myosin inhibitor for treating obstructive hypertrophic cardiomyopathy (HCM). The FDA set a PDUFA target date of September 26, 2025, with standard review and no planned advisory committee meeting.
The NDA is supported by SEQUOIA-HCM Phase 3 trial results, which showed significant improvement in exercise capacity with aficamten versus placebo. The drug demonstrated positive impacts on exercise capacity, clinical outcomes, and cardiac biomarkers, with statistically significant improvements in all 10 prespecified secondary endpoints. Treatment-emergent serious adverse events were lower in the aficamten group (5.6%) compared to placebo (9.3%).
Cytokinetics (CYTK) and Bayer have established an exclusive licensing agreement for aficamten in Japan, focusing on treating hypertrophic cardiomyopathy (HCM). The deal includes an upfront payment of €50 million to Cytokinetics, with potential additional earnings of €90 million in milestones through commercial launch (including €20 million near-term) and up to €490 million in commercial milestone payments. The collaboration involves tiered royalties on Japanese sales and joint development plans, with Bayer conducting Phase 3 trials for obstructive HCM in Japan while Cytokinetics expands its ACACIA-HCM and CEDAR-HCM trials into the region.
Cytokinetics (CYTK) presented new post-hoc analyses of GALACTIC-HF, their Phase 3 trial of omecamtiv mecarbil for heart failure, at AHA Scientific Sessions 2024. The analyses showed that the drug reduced risk of adverse cardiac outcomes in severe heart failure patients regardless of age. Among 8,232 patients studied over 21.8 months, the treatment demonstrated significant risk reductions in both age groups (<65 and ≥65 years). The drug also showed potential benefits in reducing ventricular arrhythmias (VA) risk in patients with severely reduced left ventricular ejection fraction, while maintaining a favorable safety profile.
Cytokinetics presented new data for aficamten in hypertrophic cardiomyopathy (HCM) at the American Heart Association Scientific Sessions 2024. Analysis from SEQUOIA-HCM showed aficamten improved post-exercise oxygen uptake recovery and quality of life measures. FOREST-HCM data revealed that after 12 weeks of treatment, only 3% of previously eligible patients remained candidates for septal reduction therapy, down from 35%. Real-world cost analysis of 5,129 HCM patients showed significant cost variations: male patients had higher overall costs ($71,581 vs $63,710 for females), younger patients (18-39) faced higher costs across most categories, and notable cost differences were observed across racial/ethnic groups.
Cytokinetics (CYTK) has announced its participation in the 2024 Jefferies London Healthcare Conference. The company will engage in a fireside chat scheduled for Tuesday, November 19, 2024, at 4:00 PM GMT at The Waldorf Hilton Hotel in London.
A live webcast of the discussion will be accessible through the Investors & Media section of Cytokinetics' website. The replay will remain available on the company's website for 90 days after the event concludes.
Cytokinetics (CYTK) has initiated a Phase 1 clinical study of CK-4015089 (CK-089), a fast skeletal muscle troponin activator (FSTA). The trial is a randomized, double-blind, placebo-controlled study evaluating safety, tolerability, and pharmacokinetics in healthy participants. The study includes single and multiple ascending dose cohorts, each with 10 participants. CK-089 showed promising pre-clinical results, increasing muscle force and function in animal models, suggesting potential applications in muscular dystrophy and other conditions of impaired muscle function.
Cytokinetics (CYTK) reported Q3 2024 financial results, highlighting the completion of its NDA submission for aficamten for obstructive hypertrophic cardiomyopathy treatment. The company ended Q3 with $1.3 billion in cash and investments. Q3 revenues were $0.5 million, with R&D expenses at $84.6 million and G&A expenses at $56.7 million. Net loss was $160.5 million, or $(1.36) per share. The company maintains its 2024 guidance with GAAP operating expenses of $555-575 million.
Cytokinetics (CYTK) announced six presentations scheduled for the American Heart Association Scientific Sessions 2024 in Chicago from November 16-18, 2024. The presentations focus on two key drugs: Aficamten and Omecamtiv Mecarbil.
Three presentations will discuss Aficamten's results from the SEQUOIA-HCM and FOREST-HCM trials, including oxygen uptake recovery patterns, efficacy in patients eligible for septal reduction therapy, and quality of life improvements. Two presentations will cover Omecamtiv Mecarbil's findings from the GALACTIC-HF trial, examining its effects on ventricular arrhythmias and efficacy across age groups. An additional presentation will address healthcare costs in obstructive hypertrophic cardiomyopathy patients.